OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 11:22:16 15/05/2024 pm IST | ||
| 5.61 EUR | -0.18% |
|
| Current month | -2.43% | ||
| 1 month | +4.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 5.61 | -0.18% |
| 14/24/14 | 5.62 | 0.00% |
| 13/24/13 | 5.62 | -0.35% |
| 10/24/10 | 5.64 | -0.35% |
| 09/24/09 | 5.66 | -1.74% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 11:22 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ34TM |
| ISIN | DE000SQ34TM7 |
| Date issued | 10/11/2022 |
| Strike | 105.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.82 € |
|---|---|
| Lowest since issue | 2.55 € |
| Spread | 0.01 € |
| Spread % | 0.18% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- Certificat